Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts from the ‘Licensing’ category

Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012

By on February 13, 2012

New York Skyline from Empire State 300x168 Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012 The 2012 BIO CEO & Investor conference starts today in New York.

The meeting from February 13-14 is being held at the landmark Waldorf-Astoria hotel.

I’m looking forward to seeing some of the iconic hotel features such as the 1893 lobby clock originally produced for the Chicago World Fair.

With Wall Street analysts and investors in mind, the main focus of the 14th annual conference is on publicly traded biotechnology companies.

I expect that a number of the corporate presentations will be webcast, but if you are unable to be in NYC, you can follow the #BIOCEO2012 twitter conversation below:

This is a preview of Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012. Read the full post

Leave a comment

Radotinib approved in South Korea for CML

By on January 5, 2012

IY5511 radotinib IL Yang Pharma Korea 300x141 Radotinib approved in South Korea for CML

The Yonhap news agency announced today that the South Korean equivalent of the FDA had approved Il-Yang pharmaceuticals radotinib (brand name Supect) for chronic myeloid leukemia (CML).  Radotinib is a tyrosine kinase inhibitor, also known by its development code of IY5511.

I briefly mentioned radotinib in my CML update from the ASH 2011 annual meeting.

The Yonhap release quotes an official at the Korean Centers for Disease Control and Prevention (KCDC) as saying that:

“It will be used on patients who have become resistant to existing drugs such as Gleevec, Tasigna and Sprycel.”

This is a preview of Radotinib approved in South Korea for CML. Read the full post

Leave a comment

BIO 2011 International Convention Video Review #BIO2011

By on July 1, 2011

Although I had to leave BIO 2011 early due to illness, I did shoot some video during the time I was at the meeting, and have now put this together into a short 2 minute video that you can watch below.

This post wraps up my coverage of the 2011 BIO international convention in Washington DC. Next week, I’ll be writing more about innovative science and new products in the pipeline that have caught my attention.

A happy holiday weekend to everyone in North America.

Permanent link to this post (86 words, estimated 21 secs reading time)
Leave a comment

BIO 2011 Network till you drop #BIO2011

By on June 28, 2011

Everyone at BIO 2011, the annual international convention of the Biotechnology Industry Organization (BIO) is into networking.  Sit next to someone on one of the shuttle buses, in a coffee line or in a meeting hall and a conversation will soon be struck up and business cards exchanged.  Business development, partnering and making connections is what this meeting is really about.

This is a preview of BIO 2011 Network till you drop #BIO2011. Read the full post

Leave a comment

BIO 2011: my top 10 sessions at the BIO International convention in Washington DC

By on June 18, 2011

BIO 2011 International Convention Washington DC BIO 2011: my top 10 sessions at the BIO International convention in Washington DC

I am excited to be attending, for the first time, the Biotechnology Industry Organization (BIO) international convention that takes place in Washington DC in just over a week’s time from Monday June 27 to Thursday, June 30th.

This meeting has something for everyone interested in the biotechnology industry whether it be deal making, partnering, licensing, drug discovery or personalized medicine. There are 16 specialized tracks where industry experts provide insight and best practices.

In addition, there are numerous networking and social events plus an exhibit hall that showcases the world’s biotech regions and how they are promoting innovation.

This is a preview of BIO 2011: my top 10 sessions at the BIO International convention in Washington DC. Read the full post

1 Comment

BayBio 2011 Annual Conference on Powering Global Innovation

By on April 20, 2011

Today and tomorrow, Northern California’s Life Science organization BayBio has their annual meeting.  Entitled ‘Powering Global Innovation” it’s a meeting that covers a lot of ground from deal making to partnering, emerging markets and company presentations.

According to their website, they plan to be live streaming to their website.  However, if you are interested in following the Twitter discussion (hashtag #baybio2011), you can do so using the aggregator below – just click on the play button to see the tweets:

Permanent link to this post (81 words, estimated 19 secs reading time)
Leave a comment

Artificial Retina Project shows power of collaboration to bring new products to market

By on March 14, 2011

I wrote last week about Second Sight’s European Marketing Approval for the Argus II “artificial retina”.  What this news also stands for is the success of collaboration as a route to innovation.

The Artificial Retina Project (“Restoring Sight through Science”) through which Argus II was developed is a collaborative effort between six United States Department of Energy (DOE) research institutions, 4 universities and private industry.

Each offers unique scientific knowledge and specialist expertise, without which it is unlikely the project (that is continuing with the development of a more advanced Argus III artificial retina) would have been successful.

This is a preview of Artificial Retina Project shows power of collaboration to bring new products to market. Read the full post

Leave a comment

Letter from San Francisco

By on March 5, 2011

San Francisco Golden Gate Bridge 300x225 Letter from San FranciscoI was recently in San Francisco so thought I would continue my theme of writing about biotechnology regions that I visit around the United States.

Growing up in England, I remember listening to the radio broadcasts of the late Alistair Cooke, who from 1946 to 2004 shared his “Letter from America“; the longest running radio programme ever produced.  In the pre-internet era his mixture of anecdotes, insights and reflections reminds me of modern day blogs.

This is a preview of Letter from San Francisco. Read the full post

Leave a comment

Allon Therapeutics announces promising preclinical results for davunetide in Parkinson’s Disease

By on February 24, 2011

Earlier this month the Michael J Fox Foundation (MJFF) announced that Vancouver based Allon Therapeutics had been able to improve motor function and brain pathology in a mouse model of Parkinson’s disease (PD).

MJFF funded this research with Allon Therapeutics. The preclinical study results are published in the Journal of Molecular and Cellular Neuroscience.

What makes this data interesting is that it adds further support to the potential efficacy of the company’s lead product, davunetide, in a wide range of neurodegenerative disorders.

Davunetide (AL-108) is a microtubule-interacting peptide based on an eight amino acid sequence, Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single letter code NAPVSIPQ (NAP) derived from activity-dependent neuroprotective protein (ADNP). It has been shown to have neuroprotective properties.

This is a preview of Allon Therapeutics announces promising preclinical results for davunetide in Parkinson’s Disease. Read the full post

Leave a comment